PEPTO BISMOL CAPLET - 262MG/CAPLET 262 MG
BISMUTH SUBSALICYLATE : 262 MG · DIN 02177994 · PROCTER & GAMBLE INC
Health Canada status: MARKETED
What is PEPTO BISMOL CAPLET - 262MG/CAPLET?
PEPTO BISMOL CAPLET - 262MG/CAPLET 262 MG contains BISMUTH SUBSALICYLATE : 262 MG. It is listed in the Health Canada Drug Product Database under DIN 02177994, held by PROCTER & GAMBLE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 26-May-1998. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is PEPTO BISMOL CAPLET - 262MG/CAPLET called?
Also recorded in Canada as: bismuth subsalicylate 35 MG/ML Oral Suspension [Kaopectate Reformulated Aug 2006] (US), bismuth subsalicylate 17.5 MG/ML Oral Suspension [Bismusal] (US), bismuth subsalicylate 105 MG/ML Oral Suspension [Percy Medicine] (US), bismuth subsalicylate 262 MG Powder for Oral Suspension [Estomaquil] (US), bismuth subsalicylate 525 MG Oral Tablet [Pepto-bismol] (US), bismuth subsalicylate 262 MG Chewable Tablet [Bismarex] (US), bismuth subsalicylate 262 MG Chewable Tablet [Pepto-bismol] (US), bismuth subsalicylate 17.5 MG/ML Oral Suspension [Pepto-bismol] (US), bismuth subsalicylate 35 MG/ML Oral Suspension [Pepto-bismol] (US), bismuth subsalicylate 262 MG Oral Capsule [Pepto-bismol] (US), bismuth subsalicylate 262 MG Chewable Tablet [Kaopectate Reformulated Aug 2006] (US), bismuth subsalicylate 17.5 MG/ML Oral Suspension [Kaopectate Reformulated Aug 2006] (US), bismuth subsalicylate 262 MG Oral Tablet [Kaopectate Reformulated Aug 2006] (US), bismuth subsalicylate 262 MG Oral Tablet [Pepto-bismol] (US), bismuth subsalicylate 525 MG Oral Powder (US).
Product details and regulatory record
| DIN | 02177994 |
|---|---|
| Brand name | PEPTO BISMOL CAPLET - 262MG/CAPLET |
| Generic / active ingredient | BISMUTH SUBSALICYLATE : 262 MG |
| Manufacturer | PROCTER & GAMBLE INC |
| Strength | 262 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A07BB BISMUTH PREPARATIONS |
| AHFS class | 56:04.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-May-1998 |
| Original market date | 1996-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02177994 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2177994 |
| Brand name | PEPTO BISMOL CAPLET - 262MG/CAPLET |
| Active ingredient / INN | BISMUTH SUBSALICYLATE : 262 MG |
| ATC code | A07BB |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A07 |
| AHFS class | 56:04.00 |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| Biosimilar biologic | No |
| Market authorization holder | PROCTER & GAMBLE INC |
Which pack is which?
| Strength on the label | 262 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code A07BB BISMUTH PREPARATIONS. 12 of 55 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BISMUTH CAPLETS | 262 MG | TABLET | JUNO OTC INC | MARKETED | DIN 02457121 |
| BISMUTH SUBSALICYLATE CAPLETS | 262 MG | TABLET | GUARDIAN DRUG COMPANY INC | MARKETED | DIN 02326582 |
| BISMUTH SUBSALICYLATE SUSPENSION | 17.5 MG | SUSPENSION | GUARDIAN DRUG COMPANY INC | MARKETED | DIN 02313162 |
| EXTRA STRENGTH BISMUTH | 35.2 MG | SUSPENSION | JUNO OTC INC | MARKETED | DIN 02475855 |
| EXTRA STRENGTH BISMUTH SUBSALICYLATE SUSPENSION | 35 MG | SUSPENSION | GUARDIAN DRUG COMPANY INC | MARKETED | DIN 02328453 |
| GASTROVOL LIQUID GELS | 262 MG | CAPSULE | CHURCH & DWIGHT CANADA CORP | MARKETED | DIN 02534436 |
| PEPTO BISMOL LIQUICAPS | 262 MG | CAPSULE | PROCTER & GAMBLE INC | MARKETED | DIN 02499991 |
| PEPTO-BISMOL | 17.6 MG | SUSPENSION | PROCTER & GAMBLE INC | MARKETED | DIN 02097079 |
| PEPTO-BISMOL EXTRA | 35.2 MG | SUSPENSION | PROCTER & GAMBLE INC | MARKETED | DIN 02229668 |
| PEPTO-BISMOL EXTRA CAPLET | 524 MG | TABLET | PROCTER & GAMBLE INC | MARKETED | DIN 02530759 |
Who else supplies BISMUTH PREPARATIONS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BISMUTH PREPARATIONS appears in 13 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does BISMUTH PREPARATIONS cost around the world?
BISMUTH PREPARATIONS is listed on 2 national price registers Nexara tracks, across 3 pack listings published on 2 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 1 | 2 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.